Recombination Therapeutics LLC

Philadelphia, PA

UEI
JLYJMA2WFYE3
CAGE
850Y6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
826 S 2nd St #2R, Philadelphia, PA 19147, USA
Founded
2018
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Structure based design of POL-theta inhibitors - acute myeloid leukemia (AML) is the most frequently diagnosed form… R41CA265430 National Cancer Institute (NIH) $1,157,700
Nucleotide inhibitors as precision medicine in breast cancer R41CA257002 National Cancer Institute (NIH) $399,757
Next-generation precision medicine for targeting recombination-deficient cancers R41CA239983 National Cancer Institute (NIH) $298,959

Similar vendors

Vendor Location Primary NAICS
Senex Biotechnology Inc. UEI G8XKMW3DYMQ6 Maynard, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Blood Cell Technologies LLC UEI HH9LT9M9B3N4 Setauket- East Setauket, NY 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Stemsynergy Therapeutics Inc. UEI WVEMHJFUNJ97 Miami, FL 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Triterpenoid Therapeutics Inc. UEI JA25GYTMYJP3 Boston, MA 813920 Professional Organizations
Window Therapeutics, Inc. UEI JFLXDJ3ZY975 Boston, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Recombination Therapeutics LLC is a self-certified small disadvantaged business and for-profit organization structured as a limited liability company. It is registered in SAM.gov to receive federal contracts and grants. Recombination Therapeutics LLC appears to be a biotech or pharmaceutical company focused on developing precision oncology treatments and therapies for various types of cancer.

Through federal grant awards from the National Cancer Institute of the National Institutes of Health, Recombination Therapeutics LLC has conducted research and development work related to structure-based design of polymerase theta (Pol-theta) inhibitors as a novel treatment strategy for acute myeloid leukemia (AML), particularly FLT3 (ITD)-positive AML. The company has developed small molecule Pol-theta inhibitors and studied their efficacy in combination with tyrosine kinase inhibitors for treating BRCA-deficient leukemias like AML, ALL, and CML. Additionally, Recombination Therapeutics has worked on developing nucleotide inhibitors as precision medicine for breast cancer, as well as next-generation precision medicine approaches for targeting recombination-deficient cancers more broadly. The grant funding amounts ranged from around $300,000 to over $1.1 million for these oncology research projects.

Quick answers

Is Recombination Therapeutics LLC registered in SAM.gov?

Yes. Recombination Therapeutics LLC's SAM.gov registration is active through May 15, 2027.

What is Recombination Therapeutics LLC's most recent federal award?

Recombination Therapeutics LLC's most recent federal grant award is Structure based design of POL-theta inhibitors - acute myeloid leukemia (AML) is the most frequently diagnosed form… (R41CA265430), from National Cancer Institute (NIH), on July 16, 2021.

On GovTribe

See Recombination Therapeutics LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login